New Drug To Curb Smoking Shows Positive Results

Main Category: Smoking / Quit Smoking
Also Included In: Respiratory / Asthma
Article Date: 31 Mar 2009 - 5:00 PDT


Research has shown that varenicline tartrate - a novel new drug specifically developed for smoking cessation - allows smokers to abstain from cigarettes significantly longer and more effectively than smokers using a placebo.

A paper in Respirology, published by Wiley-Blackwell, compared the efficacy of a standard 12-week regimen of varenicline for smoking cessation with a placebo on 333 subjects in 15 test sites across China, Singapore and Thailand.

"The smoking cessation rate achieved after the treatment period and the follow-up period was significantly higher with varenicline than with placebo. Likewise, the long-term quit rate for smokers treated with varenicline was also significantly higher", said Dr. Chen Wang from the Beijing Institute of Respiratory Medicine.

More than half of the smokers from the varenicline group abstained from cigarettes within the treatment period while 38% continued to abstain for the next 12 weeks after the treatment. The abstinence rate for the placebo group was significantly lower with only 31% of the participants managing to abstain during the treatment period and 25 % for the non-treatment period.

Varenicline tartrate is a selective nicotinic acetylcholine receptor which is licensed in Europe, the USA and Japan. This study further evaluates and establishes the efficacy, tolerability and safety profiles of varenicline in Asian smokers.

AboutRespirology

Respirology is a journal of international standing, publishing peer-reviewed articles of scientific excellence in clinical and experimental respiratory biology and disease and its related fields of research including thoracic surgery, internal medicine, immunology, intensive and critical care, epidemiology, cell and molecular biology, pathology, pharmacology and physiology.

About Wiley

Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for 200 years, helping people around the world meet their needs and fulfill their aspirations. Since 1901, Wiley and its acquired companies have published the works of more than 350 Nobel laureates in all categories: Literature, Economics, Physiology/Medicine, Chemistry and Peace.

Our core businesses include scientific, technical, medical and scholarly journals, encyclopedias, books, and online products and services; professional/trade publishes books, subscription products, training materials, and online applications and websites; and educational materials for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.

About Wiley-Blackwell

Wiley-Blackwell is the international scientific, technical, medical and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world's leading societies. Wiley-Blackwell publishes over 1,400 peer-reviewed journals as well as 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit http://www.wileyblackwell.com or http:// www.interscience.wiley.com.

Source
Wiley-Blackwell

• Additional
• References
• Citations